BAY-405

BAY-405 is an **oral, azaindole-based small molecule immuno-oncology agent** developed by Bayer in collaboration with DKFZ. It is a **potent and selective inhibitor of mitogen-activated protein kinase kinase kinase kinase 1**, also known as **hematopoietic progenitor kinase 1**, a serine/threonine kinase that functions as an intracellular immune checkpoint downstream of T-cell receptor signaling. By inhibiting HPK1, BAY-405 is designed to enhance antitumor T-cell activity and counter immune suppression within the tumor microenvironment, including suppression mediated by prostaglandin E2 and transforming growth factor beta. In preclinical syngeneic tumor models such as B16 melanoma and EMT6 breast cancer, BAY-405 showed T-cell-dependent antitumor activity as monotherapy and in combination with anti-PD-L1 treatment, with favorable drug-like properties and preclinical safety.

Other names

MAP4K1 inhibitorMAP-4K1 inhibitorMAP 4K1 inhibitorHPK1 inhibitorHPK-1 inhibitorHPK 1 inhibitor